Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012)

Johnson & Johnson (JNJ) posted Income from Non-Controlling Interests of -$339.0 million for Q3 2012.

Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012) Analysis & Trends

Johnson & Johnson (JNJ) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$339.0 million in Q3 2012.

  • Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$339.0 million in Q3 2012, while the trailing twelve-month figure through Dec 2013 was -$339.0 million (changed N/A YoY) and the FY2012 annual result came in at -$339.0 million, changed N/A from the prior year.
  • Income from Non-Controlling Interests steadied at -$339.0 million in Q3 2012 per JNJ's latest filing.
  • The five-year high for Income from Non-Controlling Interests was -$339.0 million in Q3 2012, with the low at -$339.0 million in Q3 2012.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 2.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 1.00 Mn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -3.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 8.00 Mn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn -

Historic Data

Download Data
DateValue
Sep 30, 2012 -339.00 Mn